BR Biopharma (NASDAQ:BRBI) Cut to “Hold” at Citigroup

Citigroup lowered shares of BR Biopharma (NASDAQ:BRBI) from a buy rating to a hold rating in a report released on Tuesday, Marketbeat Ratings reports.

Separately, Weiss Ratings raised BR Biopharma from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce”.

BR Biopharma Stock Performance

Shares of BRBI opened at $7.72 on Tuesday. BR Biopharma has a 1-year low of $7.97 and a 1-year high of $16.61. The company’s fifty day simple moving average is $11.80 and its 200 day simple moving average is $12.75.

BR Biopharma (NASDAQ:BRBI) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.09 earnings per share (EPS) for the quarter. The firm had revenue of $25.13 million for the quarter.

BR Biopharma Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Monday, August 17th were given a dividend of $0.1415 per share. This represents a $0.57 dividend on an annualized basis and a yield of 7.3%. This is a negative change from BR Biopharma’s previous quarterly dividend of $0.1470. The ex-dividend date of this dividend was Monday, August 17th. BR Biopharma’s dividend payout ratio (DPR) is presently 525.00%.

Hedge Funds Weigh In On BR Biopharma

An institutional investor recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma accounts for about 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th largest holding.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.